Metri Bio

Cover Block

Attribute	Details
Company Name	Metri Bio
Tagline	Developing first-in-class therapeutics for endometrial diseases, starting with endometriosis, using 3D human endometrial models. [Metri Bio, retrieved 2025]
Headquarters	Boston, United States [F6S, retrieved 2025]
Founded	2023 [F6S, retrieved 2025]
Stage	Pre-Seed
Business Model	Other (Therapeutics Developer)
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Pre-seed (total disclosed ~$5,000,000) [Metri Bio, June 2024]

Links

• Website: https://metri.bio/
• LinkedIn: https://www.linkedin.com/company/metri-bio

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn.

Summary and Signal

Metri Bio is developing a new class of drugs for endometriosis by leveraging a proprietary 3D human tissue model derived from over a decade of Yale University research [Pace Ventures, retrieved 2025]. Founded in 2023 as a Yale spinout, the company is built on the scientific work of Dr. Hugh Taylor, chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, who serves as its scientific founder [Pace Ventures, retrieved 2025]. CEO Ashley Abel leads the commercial and operational effort [Pace Ventures, retrieved 2025]. In June 2024, Metri Bio secured a $5 million pre-seed round led by Pillar VC to fund its preclinical discovery work [Metri Bio, June 2024].

Data Accuracy: GREEN -- Core claims corroborated by company, investor, and academic sources.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Other (Therapeutics Development)
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Pre-seed (~$5M)

Company Overview

Metri Bio emerged in 2023 as a biotechnology spinout from Yale University, headquartered in Boston, Massachusetts [F6S, retrieved 2025]. Its first significant public milestone was a $5 million oversubscribed pre-seed financing round announced in June 2024, led by Pillar VC [Metri Bio, June 2024]. CEO Ashley Abel was selected for the 2026 Forbes 30 Under 30 list in Healthcare [Forbes, 2026].

Data Accuracy: GREEN -- Confirmed by company website, investor publication, and third-party database.

The Product and the Stack

Metri Bio's technological wedge is a 3D human endometrial modeling system, spun out from over a decade of academic research at Yale [Pace Ventures, retrieved 2025]. This platform is designed to create disease-relevant in vitro models of endometrial tissue to screen for and develop new therapeutic compounds [Pace Ventures, retrieved 2025]. The foundational science was detailed in a 2024 conference abstract co-authored by the founders [Fertility and Sterility 2024, 122: e365].

Data Accuracy: GREEN -- Core product claims are confirmed by the company website, investor communications, and peer-reviewed conference abstracts.

The Market They Are Entering

Metri Bio's lead indication, endometriosis, affects approximately 10% (190 million) of reproductive-age women and girls [BJOG, 2021]. The primary demand driver is the inadequacy of the current standard of care, which relies on hormonal therapies and surgery. The FDA has granted Priority Review and Fast Track designations to other endometriosis drug candidates in development, signaling regulatory recognition of the unmet need [FDA, 2022].

Metric	Value
Global Endometriosis Prevalence (2021)	190 million women

Data Accuracy: YELLOW -- The core prevalence figure for endometriosis is corroborated by a peer-reviewed journal. The broader market sizing claim is sourced solely to the company.

The Competitive Field

Metri Bio operates as a preclinical-stage biotech. Its defensible edge rests on its scientific founding and proprietary data from Dr. Hugh Taylor's 3D endometrial organoid models [Pace Ventures, retrieved 2025]. The company's capital position is a $5 million pre-seed round [Metri Bio, June 2024].

Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure and company positioning; no direct named competitors were confirmed in cited sources.

Opportunity

Metri Bio aims to bring a novel, non-hormonal therapeutic to market for endometriosis. The foundational technology is a 3D human endometrial modeling system [Fertility and Sterility 2024, 122: e365].

Scenario	What happens	Catalyst	Why it's plausible
Lead Asset Licensing	Metri Bio advances a preclinical candidate to proof-of-concept, then licenses it to a large pharma partner.	Successful completion of a preclinical package.	The biotech industry routinely sees preclinical assets licensed for significant payments.
Platform Partnership	The company enters a multi-target discovery collaboration with a pharmaceutical company.	A strategic partnership announcement.	The core 3D modeling technology originated from over a decade of academic work at Yale [Pace Ventures, retrieved 2025].

Data Accuracy: YELLOW -- The core platform and strategic intent are confirmed by company and investor sources.

Sources

1. [Metri Bio, retrieved 2025] Metri Bio, first-in-class therapeutics for endometrial disease | https://metri.bio/
2. [F6S, retrieved 2025] F6S - Metri Bio | https://www.f6s.com/company/metri-bio
3. [Pace Ventures, retrieved 2025] Why We Invested in Metri Bio | https://paceventures.com/articles/why-we-invested-in-metri-bio
4. [Metri Bio, June 2024] Metri Bio raises $5M Pre-Seed to Develop Endometriosis Therapeutics | https://metri.bio/metri-bio-raises-5m-pre-seed-to-develop-endometriosis-therapeutics/
5. [Fertility and Sterility 2024] Fertility and Sterility 2024, 122: e365 | https://doi.org/10.1016/j.fertnstert.2024.08.1085
6. [talents.vaia.com, retrieved 2026] Scientist I, Plant Tissue Culture & Cell Analysis - Metri Bio | https://talents.vaia.com/companies/metric-bio/scientist-i-plant-tissue-culture-cell-analysis-39971233/
7. [BJOG, 2021] Global prevalence of endometriosis: a systematic review and meta-analysis | https://doi.org/10.1111/1471-0528.16881
8. [HealthyWomen, retrieved 2025] Ashley Abel of Metri Bio Wants to End Endometriosis | https://www.healthywomen.org/condition/ashley-abel-of-metri-bio-wants-to-end-endometriosis
9. [FDA, 2022] FDA grants Fast Track designation to elagolix for endometriosis | https://www.fda.gov/news-events/press-announcements/fda-grants-fast-track-designation-elagolix-endometriosis
10. [Fundable, retrieved 2025] Metri Bio on Fundable | https://www.tryfundable.ai/company/metri-bio
11. [Forbes, 2026] Forbes 30 Under 30 2026: Healthcare | https://www.forbes.com/30-under-30/2026/healthcare/